Abstract:BACKGROUND:Activating the Stimulator of Interferon Genes (STING) adaptor incites antitumor immunity against immunogenic tumors in mice, prompting clinical trials to test STING activators. However, STING signaling in the tumor microenvironment (TME) during development of Lewis lung carcinoma (LLC) suppresses antitumor immunity to promote tumor growth. We hypothesized that local immune balance favoring suppression of antitumor immunity also attenuates antitumor responses following STING activation. The purpose of this study was to evaluate how STING activation impacts antitumor responses in mice bearing LLC tumors. METHODS:Mice bearing established LLC tumors were treated with synthetic cyclic diadenyl monophosphate (CDA) to activate STING. Mice were monitored to assess LLC tumor growth, survival and protective antitumor immunity. Transcriptional and metabolic analyses were used to identify pathways responsive to CDA, and mice were co-treated with CDA and drugs that disrupt these pathways. RESULTS:CDA slowed LLC tumor growth but most CDA-treated mice (77%) succumbed to tumor growth. No evidence of tumor relapse was found in surviving CDA-treated mice at experimental end points but mice were not immune to LLC challenge. CDA induced rapid increase in immune regulatory pathways involving programmed death-1 (PD-1), indoleamine 2,3 dioxygenase (IDO) and cyclooxygenase-2 (COX2) in the TME. PD-1 blockade enhanced antitumor responses to CDA and increased mouse survival but mice did not eliminate primary tumor burdens. Two IDO inhibitor drugs had little or no beneficial effects on antitumor responses to CDA. A third IDO inhibitor drug synergized with CDA to enhance tumor control and survival but mice did not eliminate primary tumor burdens. In contrast, co-treatments with CDA and the COX2-selective inhibitor celecoxib controlled tumor growth, leading to uniform survival without relapse, and mice acquired resistance to LLC re-challenge and growth of distal tumors not exposed directly to CDA. Thus, mice co-treated with CDA and celecoxib acquired stable and systemic antitumor immunity. CONCLUSIONS:STING activation incites potent antitumor responses and boosts local immune regulation to attenuate antitumor responses. Blocking STING-responsive regulatory pathways synergizes with CDA to enhance antitumor responses, particularly COX2 inhibition. Thus, therapy-induced resistance to STING may necessitate co-treatments to disrupt regulatory pathways responsive to STING in patients with cancer.

Cutting Edge: STING Mediates Protection Against Colorectal Tumorigenesis by Governing the Magnitude of Intestinal Inflammation

STING-mediated Syk Signaling Attenuates Tumorigenesis of Colitis-associated Colorectal Cancer Through Enhancing Intestinal Epithelium Pyroptosis

Advances in the Prerequisite and Consequence of STING Downstream Signalosomes

Cytosolic sensor STING in mucosal immunity: a master regulator of gut inflammation and carcinogenesis

Intrinsic STING Switches off Pathogenetic Programs of Th1 Cells to Inhibit Colitis

Synthetic Enforcement of STING Signaling in Cancer Cells Appropriates the Immune Microenvironment for Checkpoint Inhibitor Therapy.

STING Controls Intestinal Homeostasis Through Promoting Antimicrobial Peptide Expression in Epithelial Cells.

STING Signaling in Tumorigenesis and Cancer Therapy: A Friend or Foe?

STING-mediated disruption of calcium homeostasis chronically activates ER stress and primes T cell death

STING-mediated DNA sensing in cancer immunotherapy

STING Licensing of Type I Dendritic Cells Potentiates Antitumor Immunity

Regulating STING in health and disease

The balance of STING signaling orchestrates immunity in cancer

Targeting the STING Pathway in Tumor-Associated Macrophages Regulates Innate Immune Sensing of Gastric Cancer Cells.

STING an essential trigger of DNA-mediated innate immune signaling. (P1258)

STING enhances cell death through regulation of reactive oxygen species and DNA damage

Interferon-Independent Activities of Mammalian STING Mediate Antiviral Response and Tumor Immune Evasion.

STING is a cell-intrinsic metabolic checkpoint restricting aerobic glycolysis by targeting HK2

Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity.

STING Promotes the Growth of Tumors Characterized by Low Antigenicity Via IDO Activation.

Suppression of systemic autoimmunity by the innate immune adaptor STING